• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

    22.21 -0.01 (-0.05%)
    Streaming Delayed Price Updated: 2:09 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,285,605
    Open 21.24
    Bid (Size) 22.20 (2)
    Ask (Size) 22.22 (2)
    Prev. Close 22.22
    Today's Range 21.07 - 22.34
    52wk Range 16.10 - 35.72
    Shares Outstanding 116,457,008
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
    During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent... 
    Via Benzinga
    Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday. 
    Via Benzinga
    Topics Stocks

    Performance

    YTD
    -33.0%
    -33.0%
    1 Month
    -20.5%
    -20.5%
    3 Month
    +20.7%
    +20.7%
    6 Month
    -8.5%
    -8.5%
    1 Year
    -27.4%
    -27.4%

    More News

    Read More
    Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Topics Artificial Intelligence
    Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
    Via Stocktwits
    Earnings Scheduled For July 31, 2025
    Via Benzinga
    Earnings Scheduled For May 7, 2025
    Via Benzinga
    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
    Via Stocktwits
    Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
    Via Chartmill
    Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
    Via Benzinga
    Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
    Via Stocktwits
    FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
    Via Benzinga
    Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
    Via Benzinga
    Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.; Sobi
    Via GlobeNewswire
    Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
    Via Benzinga
    Why Apellis Pharmaceuticals Wilted on Wednesday
    Via The Motley Fool
    Topics Earnings
    Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
    Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
    What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
    The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 22.21
    When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 09/26/25 02:09 PM ET
    What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.59B
    How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Apellis Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.